Search This Blog

Monday, July 10, 2023

Better Therapeutics Receives FDA Authorization for AspyreRx for Type 2 Diabetes

 First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone

In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c

Company to host conference call and webcast on July 11 at 8:30 a.m. ET

Better Therapeutics will hold a conference call on July 11 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time to discuss the FDA authorization of AspyreRx. Investors and the general public may access a live webcast of the call by visiting https://edge.media-server.com/mmc/p/adggoags

https://finance.yahoo.com/news/better-therapeutics-receives-fda-authorization-203000933.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.